Landscape Capital Management L.L.C. Acquires New Shares in Johnson & Johnson $JNJ

Key Points

• Landscape Capital Management L.L.C. acquired a new stake in Johnson & Johnson, purchasing nearly 3,000 shares valued at approximately $497,000 in the first quarter.
• Multiple hedge funds have increased their investments in Johnson & Johnson, with institutional investors owning 69.55% of the company's stock.
• Johnson & Johnson recently reported quarterly earnings of $2.77 EPS, surpassing estimates, and declared a quarterly dividend of $1.30 per share, reflecting a 2.9% yield.

Landscape Capital Management L.L.C. purchased a new position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,995 shares of the company's stock, valued at approximately $497,000.

Several other institutional investors also recently modified their holdings of JNJ. Highline Wealth Partners LLC increased its holdings in Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the first quarter valued at $47,000. von Borstel & Associates Inc. acquired a new stake in Johnson & Johnson in the first quarter valued at $49,000. Harvest Fund Management Co. Ltd acquired a new stake in Johnson & Johnson in the first quarter valued at $52,000. Finally, Capital A Wealth Management LLC acquired a new stake in Johnson & Johnson in the fourth quarter valued at $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Up 0.9%

NYSE JNJ traded up $1.65 during trading hours on Friday, hitting $177.10. The company's stock had a trading volume of 6,939,753 shares, compared to its average volume of 8,300,538. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a market capitalization of $426.52 billion, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.26 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The company's 50-day simple moving average is $165.99 and its two-hundred day simple moving average is $160.06.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same quarter last year, the firm earned $2.82 EPS. The firm's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on JNJ shares. Royal Bank Of Canada increased their price target on Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Morgan Stanley increased their price target on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, Guggenheim reiterated a "neutral" rating and set a $167.00 price target (up from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $176.29.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.